Survival after Gastrectomy in Node-Negative Gastric Cancer: A Review and Meta-Analysis of Prognostic Factors.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4500595)

Published in Med Sci Monit on July 02, 2015

Authors

Yanming Zhou1, Feng Yu2, Lupeng Wu1, Feng Ye1, Leilei Zhang3, Yumin Li4

Author Affiliations

1: Department of Hepato-Biliary-Pancreato-Vascular Surgery, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China (mainland).
2: Department of Hepatobiliary Surgery, The 101th Hospital of Chinese PLA, Wuxi, Jiangsu, China (mainland).
3: Department of Anaesthesiology, Second Hospital of Jilin University, Changchun, Jilin, China (mainland).
4: Department of General Surgery, Second Hospital of Lanzhou University, Lanzhou, Gansu, China (mainland).

Articles citing this

Current status of lymph node micrometastasis in gastric cancer. Oncotarget (2017) 0.75

Articles cited by this

Global cancer statistics. CA Cancer J Clin (2011) 185.92

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (2012) 6.83

Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol (2011) 6.18

A multicentric Western analysis of prognostic factors in advanced, node-negative gastric cancer patients. Ann Surg (2010) 2.27

Prognostic factors and recurrence pattern in node-negative advanced gastric cancer. Eur J Surg Oncol (2012) 2.05

Prognostic impact of lymphatic and/or blood vessel invasion in patients with node-negative advanced gastric cancer. Ann Surg Oncol (2002) 1.40

Biologic predictors of survival in node-negative gastric cancer. Ann Surg (2003) 1.37

Effect of lymph node number on survival of patients with lymph node-negative gastric cancer according to the 7th edition UICC TNM system. PLoS One (2012) 1.20

Lymphatic invasion using D2-40 monoclonal antibody and its relationship to lymph node micrometastasis in pN0 gastric cancer. Br J Cancer (2005) 1.20

Overexpression of both VEGF-A and VEGF-C in gastric cancer correlates with prognosis, and silencing of both is effective to inhibit cancer growth. Int J Clin Exp Pathol (2013) 1.13

Clinicopathologic study of node-negative advanced gastric cancer and analysis of factors predicting its recurrence and prognosis. Am J Surg (2012) 1.13

Prognostic indicators in node-negative advanced gastric cancer patients. J Surg Oncol (2010) 1.11

Prognostic factors in patients with node-negative gastric carcinoma: a comparison with node-positive gastric carcinoma. World J Gastroenterol (2006) 1.10

Prognostic indicators for survival after curative resection for patients with carcinoma of the stomach. Dig Dis Sci (1997) 1.05

Clinicopathologic characteristics and outcome indicators in node-negative gastric cancer. J Surg Oncol (2000) 1.02

Prognostic impact of lymphatic invasion in patients with node-negative gastric cancer. J Surg Oncol (2009) 1.01

Factors Associated With Recurrence and Survival in Lymph Node-negative Gastric Adenocarcinoma: A 7-Institution Study of the US Gastric Cancer Collaborative. Ann Surg (2015) 0.99

Survival predictors in patients with node-negative gastric carcinoma. J Gastroenterol Hepatol (2007) 0.99

Impact on survival of the number of lymph nodes removed in patients with node-negative gastric cancer submitted to extended lymph node dissection. Eur J Surg Oncol (2011) 0.99

Adverse prognosis of clustered-cell versus single-cell micrometastases in pN0 early gastric cancer. J Surg Oncol (2011) 0.98

Prognostic analysis in node-negative gastric cancer patients in China. Tumour Biol (2010) 0.95

Prognostic significance of lymphovascular invasion in node-negative gastric cancer. World J Surg (2015) 0.95

Prognostic factors on overall survival in lymph node negative gastric cancer patients who underwent curative resection. J Gastric Cancer (2012) 0.94

Comparison of disease-specific survival in the United States and Korea after resection for early-stage node-negative gastric carcinoma. J Surg Oncol (2012) 0.93

Lymphatic endothelial cell-secreted CXCL1 stimulates lymphangiogenesis and metastasis of gastric cancer. Int J Cancer (2011) 0.92

Prognosis of gastric cancer patients with node-negative metastasis following curative resection: outcomes of the survival and recurrence. Can J Gastroenterol (2008) 0.90

Prognostic value of number of examined lymph nodes in patients with node-negative gastric cancer. World J Gastroenterol (2014) 0.88

Prognostic factors in patients with node-negative gastric cancer: a single center experience from China. J Gastrointest Surg (2012) 0.86

Prognostic impact of venous invasion in stage IB node-negative gastric cancer. Gastric Cancer (2014) 0.85

Prognostic factors in patients with node-negative gastric cancer: an Indian experience. World J Surg Oncol (2011) 0.83

Efficacy of prophylactic extended lymphadenectomy with gastrectomy for patients with node-negative advanced gastric carcinoma. Hepatogastroenterology (2008) 0.83

Prognostic significance of intraoperative chemotherapy and extensive lymphadenectomy in patients with node-negative gastric cancer. J Surg Oncol (2011) 0.82

Does tumor size improve the accuracy of prognostic predictions in node-negative gastric cancer (pT1-4aN0M0 stage)? PLoS One (2014) 0.82

Lymphangiogenic and angiogenic microvessel density in chinese patients with gastric carcinoma: correlation with clinicopathologic parameters and prognosis. Asian Pac J Cancer Prev (2013) 0.80

Prognostic factors for patients with node-negative gastric cancer: Can extended lymph node dissection have a survival benefit? J Surg Oncol (2006) 0.79

Preoperative administration of bevacizumab is safe for patients with colorectal liver metastases. World J Gastroenterol (2013) 0.79

Predictive factors for survival and recurrence rate in patients with node-negative gastric cancer--a European single-centre experience. Langenbecks Arch Surg (2014) 0.79

Therapeutic strategy for patients with pN0 gastric carcinoma. J Surg Oncol (2006) 0.77

Do patients with pN0 gastric cancer benefit from prophylactic extended lymphadenectomy? Surg Oncol (2011) 0.77